Are Patients with Multiple Endocrine Neoplasia Type I Prone to Premature Death?
Autor: | W. Scott Harmsen, Patrick G. Dean, David R. Farley, Geoffrey B. Thompson, Clive S. Grant, Jon A. van Heerden, Duane M. Ilstrup |
---|---|
Rok vydání: | 2000 |
Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Population Risk Assessment Gastroenterology Coronary artery disease Age Distribution Life Expectancy Cause of Death Internal medicine Confidence Intervals Multiple Endocrine Neoplasia Type 1 medicine Humans Sex Distribution Child education Aged Retrospective Studies Cause of death education.field_of_study business.industry Middle Aged medicine.disease Survival Analysis United States Surgery Cardiac surgery medicine.anatomical_structure Cardiothoracic surgery Population study Female business Pancreas Abdominal surgery |
Zdroj: | World Journal of Surgery. 24:1437-1441 |
ISSN: | 1432-2323 0364-2313 |
DOI: | 10.1007/s002680010237 |
Popis: | Multiple endocrine neoplasia type I (MEN-I) is an autosomal dominant disorder characterized by endocrinopathies involving the anterior pituitary gland, parathyroid glands, and pancreas. The long-term prognosis for patients affected with this disorder is uncertain. To better characterize this prognosis, we performed a retrospective review of all patients with MEN-I treated at a single institution during the period 1951–1997. A group of 233 patients served as the study population. Their records were analyzed for confirmation of diagnosis, treatments received, long-term survival, and cause of death. Altogether, 108 eight male patients (46%) and 125 female patients (54%) were identified. At the conclusion of the study, 164 (70%) were alive and 69 (30%) were deceased, with a median follow-up for patients alive at last contact of 13.4 years (range < 1 month to 54.3 years). The cause of death was reliably obtained in 60 patients. Of these patients, 17 (28%) died of causes related to MEN-I, most commonly metastatic islet cell tumors (10 patients). The remaining patients died of causes unrelated to MEN-I, most commonly coronary artery disease and nonendocrine malignancies (14% each). The overall 20-year survival of MEN-I patients was 64% (95% CI was 56–72%), and that of an age- and gender-matched upper Midwest population was 81% (p < 0.001). Patients with MEN-I appear to be at increased risk of premature death. Earlier diagnosis and treatment of potentially malignant pancreatic islet cell neoplasms may result in a decrease of this premature mortality. |
Databáze: | OpenAIRE |
Externí odkaz: |